Scientists have shown for the first time that injectable materials are safe and feasible to treat heart disease

BEIJING, Sept. 11 (Reporter Sun Self-Law) Reporters from China
Institute of Genetics and Developmental Biology (
Institute of Genetic Development) was informed that the Institute Dai Jianwu regenerative medicine research team and Nanjing Gulou Hospital Professor Wang Dongjin team, The first international clinical study to develop injectable stent (collagen) materials in combination with stem cell transplantation to treat ischemic heart disease has made a major breakthrough, proving for the first time the clinical safety and feasibility of injectable materials combined stem cells for heart disease treatment, and showing good application prospects, and laying the foundation for subsequent large-sample clinical trials.
This is the first time that Dai Jianwu team has successfully carried out a series of original achievements of regenerative medicine, such as ovarian premature aging regeneration repair, endometrial regeneration repair, spinal cord injury regeneration repair, and so on, to explore the heart muscle regeneration of another important original achievement. The latest paper has been published online by JAMA Network Open, a sub-journal of the Journal of the American Medical Association.
Dai Jianwu team and Wang Dongjin team of the first international injectable collagen stent material combined with stem cell transplantation to treat ischemic heart disease clinical research, its basic entry criteria for heart function less than 45% of the need for bridge surgery of the old heart attack patients. The subjects of the composite group were randomly divided into bridge surgery group, bridge surgery injection interstumin stem cell group, and bridge surgery simultaneous injection interstumin stem cell and glue raw material group.
The first patients recruited in this clinical study were admitted to the group on March 1, 2016, after more than 3 years of efforts, a total of 50 patients in the group, completed 44 patients after surgery 1-year follow-up, the results showed that cell and material transplant safety is good, in malignant events (death, tumor, persistent titration, heart failure re-entry, heart rhythm disorders, etc.) incidence, biochemical indicators, immune indicators and other aspects of the control group no significant difference.
Compared to the control group, co-stem cell transplantation of glue raw materials significantly reduced the volume of heart infarction in patients after 1 year, and the patient's quality of life and heart rating improved, and the effect was particularly effective in patients with preoperative conditions (cardiac blood test scores less than 40%): in bridge-top In the first year after the combined injection of stem cells and glue raw materials, the heart blood test score increased by an average of 9.35%, while the control group increased by 6.59% (bridge surgery combined stem cell transplantation group) and 3.62% (separate bridge surgery group).Genetic Development Institute said that Dai Jianwu team has long been engaged in the research of functional biological materials for regenerative medicine, over the years successfully developed a good biocompitive collagen stent that can be used for intramyal injection, can provide stable extracellular substation support for cells, injection into damaged cardiomyopathy tissue can effectively limit the spread of cells from the damaged site, help reshaping myocardial regeneration to repair the microenve environment. The material has completed product standardization research, and obtained the China Food and Drug Inspection Research Institute and other authoritative institutions of product technical requirements certification, biosecurity testing, immuno evaluation, virus inactivation testing and other reports, to meet the quality standards of clinical research implantable medical devices.
In the past 10 years, Dai Jianwu team and Wang Dongjin team have previously cooperated in conducting preclinical large animal experiments, and on the basis of a clear safety and effective evaluation of test materials and cell transplantation in animal experiments, the team further developed clinical trial programs, completed ethical reviews and international clinical research registrations, conducted randomized controlled clinical studies of injectable plastic raw materials combined with umbilical cord-filled stem cells to treat ischemic heart disease, and achieved this major breakthrough.
it understood that myocardial infarction is? Statistics show that at least 2.5 million new myocardial infarctions occur in China each year, and more than 1 million people die each year from myocardial infarctions and their complications. This injectable collagen stent material combined with stem cell transplantation to treat heart disease clinical research has made a major breakthrough, will hopefully bring more "regeneration" hope for such patients.